NCT00356031 · STUDY IN CONTEXT

Bevacizumab and Radiation Therapy for Sarcomas

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

The count of participants with greater than or equal to 80% pathological necrosis in the resected specimen following neoadjuvant bevacizumab and radiation.

Source null

→

secondary · POSTED

The percentage change in median microvessel density (MVD) after Bevacizumab treatment alone

Source null

→

secondary · POSTED

The percentage reduction in blood flow, blood volume,and permeability surface area of the tumor following combination therapy as determined by perfusion CT (computerized tomography) scan. The percent change represents the combined average percent change for flow, volume, and permeability together.

Source null

→

secondary · POSTED

The number of patients with local recurrence after a median follow-up of 24 months. Local recurrence is defined as disease progression (new cancer growth) at the primary cancer site.

Source null

→

secondary · POSTED

The number of participants with distant recurrence at the time of last follow-up. Distant recurrence is when cancer has spread (metastasized) to areas farther away from where the primary cancer site is.

Source null

→

secondary · POSTED

The median amount of time from the end of treatment until to distant recurrence. Distant recurrence is when cancer spreads to areas in the body away from the primary cancer site.

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-liposarcoma
nct id: NCT00356031
trial label: Bevacizumab and Radiation Therapy for Sarcomas
applicability: narrower
applicability note: Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 6
harms Count: 1
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-liposarcoma
nct id
NCT00356031
outcome key
om-0000
source section id
NCT00356031-om-0000
source outcome index
0
endpoint
Objective Response Rate for Neoadjuvant Bevacizumab Combined With Radiation Therapy for Intermediate and High-risk Soft Tissue Sarcomas.
endpoint definition
The count of participants with greater than or equal to 80% pathological necrosis in the resected specimen following neoadjuvant bevacizumab and radiation.
time origin
3 years
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-liposarcoma
nct id
NCT00356031
outcome key
om-0001
source section id
NCT00356031-om-0001
source outcome index
1
endpoint
Change in Median Microvessel Density (MVD) After Bevacizumab Alone
endpoint definition
The percentage change in median microvessel density (MVD) after Bevacizumab treatment alone
time origin
baseline and 3 years
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-liposarcoma
nct id
NCT00356031
outcome key
om-0002
source section id
NCT00356031-om-0002
source outcome index
2
endpoint
Average Change in Blood Flow, Blood Volume,and Permeability Surface Area
endpoint definition
The percentage reduction in blood flow, blood volume,and permeability surface area of the tumor following combination therapy as determined by perfusion CT (computerized tomography) scan. The percent change represents the combined average percent change for flow, volume, and permeability together.
time origin
3 years
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-liposarcoma
nct id
NCT00356031
outcome key
om-0003
source section id
NCT00356031-om-0003
source outcome index
3
endpoint
Local Control Rate
endpoint definition
The number of patients with local recurrence after a median follow-up of 24 months. Local recurrence is defined as disease progression (new cancer growth) at the primary cancer site.
time origin
3 years
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-liposarcoma
nct id
NCT00356031
outcome key
om-0004
source section id
NCT00356031-om-0004
source outcome index
4
endpoint
Distant Recurrence
endpoint definition
The number of participants with distant recurrence at the time of last follow-up. Distant recurrence is when cancer has spread (metastasized) to areas farther away from where the primary cancer site is.
time origin
3 years
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-liposarcoma
nct id
NCT00356031
outcome key
om-0005
source section id
NCT00356031-om-0005
source outcome index
5
endpoint
Disease Free Survival
endpoint definition
The median amount of time from the end of treatment until to distant recurrence. Distant recurrence is when cancer spreads to areas in the body away from the primary cancer site.
time origin
3 years
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-liposarcoma
nct id
NCT00356031
outcome key
om-0000
arm key
OG000
arm label
Bevacizumab, Radiation, and Surgery
regimen
Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT) Bevacizumab: Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses Radiation Therapy: External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good. Surgery: Surgery is performed 6-7 weeks after completion of neoadjuvant therapy.
analyzed count
20
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00356031-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-liposarcoma
nct id
NCT00356031
outcome key
om-0001
arm key
OG000
arm label
Bevacizumab, Radiation, and Surgery
regimen
Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT) Bevacizumab: Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses Radiation Therapy: External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good. Surgery: Surgery is performed 6-7 weeks after completion of neoadjuvant therapy.
analyzed count
20
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00356031-om-0001#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-liposarcoma
nct id
NCT00356031
outcome key
om-0002
arm key
OG000
arm label
Bevacizumab, Radiation, and Surgery
regimen
Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT) Bevacizumab: Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses Radiation Therapy: External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good. Surgery: Surgical resection is performed 6-7 weeks after completion of neoadjuvant therapy.
analyzed count
20
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00356031-om-0002#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-liposarcoma
nct id
NCT00356031
outcome key
om-0003
arm key
OG000
arm label
Bevacizumab, Radiation, and Surgery
regimen
Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT) Bevacizumab: Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses Radiation Therapy: External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good. Surgery: Surgery is performed 6-7 weeks after completion of neoadjuvant therapy.
analyzed count
20
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00356031-om-0003#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-liposarcoma
nct id
NCT00356031
outcome key
om-0004
arm key
OG000
arm label
Experimental: Bevacizumab, Radiation, and Surgery
regimen
Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT) Bevacizumab: Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses Radiation Therapy: External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good. Surgery: Surgery is performed 6-7 weeks after completion of neoadjuvant therapy.
analyzed count
20
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00356031-om-0004#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-liposarcoma
nct id
NCT00356031
outcome key
om-0005
arm key
OG000
arm label
Experimental: Bevacizumab, Radiation, and Surgery
regimen
Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT) Bevacizumab: Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses Radiation Therapy: External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good. Surgery: Surgery is performed 6-7 weeks after completion of neoadjuvant therapy.
analyzed count
20
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00356031-om-0005#groups/OG000

harms

release id
clinical-indications-draft-1
disease state id
ds-liposarcoma
nct id
NCT00356031
harm key
EG000
source section id
NCT00356031-ae
event group key
EG000
event group label
Bevacizumab, Radiation, and Surgery
serious affected
3
serious at risk
20
other affected
20
other at risk
20
frequency threshold
0
collection period
3 years
event definition
Laboratory tests and physical exams were performed as a part of routine study visits.
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice